ALK positive is a suspect disease in the field of blood tumors, clinical performance is complex and often involves multi-system fatigue. Early identification and normalisation of the diagnosis is essential for improving the prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory examination and pathological activation.
A platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many formerly difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions, adapted to timely regimens according to disease changes.
Multi-disciplinary collaboration (MDT) is particularly important for the integrated management of ALK positives for interstitial large cell lymphoma. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.